Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases
Sign Up to like & getrecommendations! Published in 2025 at "Leukemia"
DOI: 10.1038/s41375-025-02594-7
Abstract: Myelofibrosis (MF) in 50% of cases is driven by an activating JAK2 mutation, mostly V617F. Ruxolinitib is approved for the treatment of MF. Responses to ruxolitinib in MF are of limited duration. Unexpectedly, treatment of… read more here.
Keywords: jak2 hyperphosphorylation; jak2; ruxolitinib; activation loop ... See more keywords